What benefits can lixisenatide provide when added to basal insulin regimen?
Read More »Managing Editor, Diabetes in Control
Empagliflozin May Have Beneficial Long-Term Renal Effects
Empagliflozin might not only decrease the risk of cardiovascular events in patients with type 2, but also renal events.
Read More »Evaluating the Role of Liraglutide in Type I Diabetes
Could GLP-1 inhibitors be a useful adjunct therapy in type I diabetes?
Read More »Question #851
Here's another test of your graph-interpreting skills! Follow the link to see this graph at full size and indicate the parameter that best describes Curve 3.
1. Insulin Secretion
2. Postprandial glucose
3. Fasting glucose
4. Insulin Resistance
Early Short-term Intensive Insulin Causes the Remission of Type 2 Diabetes
Starting patients diagnosed within the last 7 years on 2-4 weeks of intensive insulin therapy could help keep them off additional medications for at least 48 weeks.
Read More »Fenofibrate Therapy in Diabetic Retinopathy
Studies suggest fenofibrate can prevent microvascular changes, decrease need for surgery.
Read More »Chronic Kidney Disease and the Incidence of Diabetes
Tighter glucose and blood pressure control found to decrease incidence.
Read More »Once-Monthly Exenatide Shows Promising Results for Adequate Glucose Control
A phase 2 randomized controlled trial demonstrated clinically significant changes in glycemic control.
Read More »Metabolic Effects of Metformin in Patients with Acute Renal Failure
Metformin use has been associated with significant disturbances in acid-base balance.
Read More »Could Influenza Vaccination Prevent More Than Just the Flu?
Influenza vaccination may reduce cardiac-related hospital admissions and all cause mortality in patients with diabetes.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.